•  
  •  
 

Subject Area

Internal Medicine

Article Type

Original Study

Abstract

Objective The aim was to evaluate the level of serum calcium and the serum level of high-sensitivity C-reactive protein (hsCRP) in patients with psoriasis. Background Psoriasis is a systemic chronic inflammatory disease of the skin with associated comorbidity. The most detrimental aspect of psoriasis is the concurrent physical comorbidities, such as cardiovascular disease, obesity, diabetes, metabolic syndrome, inflammatory bowel disease, and psoriatic arthritis that contribute to decreased longevity. Psoriasis is one of the skin diseases that have been found to show disturbance in systemic calcium metabolism. CRP is one of the acute-phase reactant proteins, and its blood level increases during inflammatory reactions. There is a link between the concentration of CRP and cardiovascular disease development in psoriatic patients. Patients and methods Psoriatic patients (n = 40) and age, sex-matched, and BMI-matched healthy controls (n = 40) were enrolled. Serum levels of hsCRP were measured by enzyme-linked immunosorbent assay, and assessment of serum calcium was done using enzymatic colorimetric technique. Results Serum calcium (P < 0.001) and serum hsCRP (P < 0.001) showed significant differences compared with controls. Conclusion Several biomarkers are altered in patients with psoriasis. In particular, decrease in serum calcium and increase in serum hsCRP could be of interest for further studies. A longitudinal observation study on levels of these biomarkers in response to treatment as well as a correlation of these markers with the development of concomitant diseases in patients with moderate-to-severe psoriasis should be initiated.

Download

Share

COinS